Literature Review: Mekanisme Resistensi Kemoterapi Berbasis Platinum

Authors

  • Amelia Rizky Khalidah Fakultas Kedokteran, Universitas Lampung

DOI:

https://doi.org/10.26630/jk.v11i1.1537

Keywords:

Cisplatin, Mechanism, Resistence.

Abstract

Cisplatin is a type of platinum-based chemotherapy that is often used in the spectrum of solid neoplasms, including the ovaries, testicles, urinary vesicles, colorectal, lungs, and head-neck. The clinical success of platinum-based chemotherapy, however, is limited to side effects and the incidence of treatment resistance. Resistance has limited the efficacy of these agents in most diseases, so further knowledge is needed on how the resistance mechanism can occur so that further development can be carried out. Molecular mechanism of cisplatin resistance. Malignant cells can lose their sensitivity to the cytostatic/cytotoxic activity of cisplatin as a result of genetic or epigenetic damage. These changes can affect processes that precede the actual binding of cisplatin to its targets (pre-target resistance), potentiating the cell's ability to repair molecular damage caused by cisplatin (resistance at the target level) and damaging the signal transmission that usually imparts damage caused by cisplatin in apoptosis (post-target resistance) or stimulates pro-survival signaling that counteracts the cytotoxicity of cisplatin even though it usually does not occur by this drug (target resistance).

References

Chen, S., &Chang, J. (2019). New Insights Into Mechanisms Of Cisplatin Resistance : From Tumor Cell To Microenvironment. Int. J. Mol. Sci. 20(4136), 1–21.

Dilruba, S., & Kalayda, G. (2016). V.Platinum-Based Drugs: Past, Present And Future. Cancer Chemother Pharmacol. 77(6), 1103-1124..

Florea, A., & Büsselberg, D. (2011). Cisplatin As An Anti-Tumor Drug: Cellular Mechanisms Of Activity, Drug Resistance And Induced Side Effects. Cancers. (3), 1351-1371.

Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., … Kroemer, G. (2011). Molecular Mechanisms Of Cisplatin Resistance. Oncogene. 31(15), 1869-1883.

Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., & Castedo, M. (2014). Systems Biology Of Cisplatin Resistance: Past, Present And Future. Cell Death And Disease. 5(5), E1257-18.

Hato, S. V, Khong, A., Vries, I. J. M. De, & Lesterhuis, W. J. (2014). Molecular Pathways : The Immunogenic Effects Of Platinum-Based Chemotherapeutics. American Association Fo Cancer Research. (1), 2831-2838.

Holohan, C., Schaeybroeck, S. Van, Longley, D. B., & Johnston, P. G. (2013). Cancer Drug Resistance : An Evolving Paradigm. Nature Publishing Group. 13(10), 714-726.

HZ, Z., YQ, Q., WJ, Z., B, X., AM, D., & LiangAB. (2011). Proteomic Analysis Identified DJ-1 As A Cisplatin Resistant Marker In Non-Small Cell Lung Cancer. Int J Mol Sci, (12), 3489-3499.

Kelland, L. (2007). The Resurgence Of Platinum-Based Cancer Chemotherapy. Nature. 7 (AUGUST), 573-584.

Longacre, M., Snyder, N., & Sarkar, S. (2014). Drug Resistance In Cancer : An Overview. Cancers, (6), 1769–1792.

Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008). Platinum Resistance : The Role Of DNA Repair Pathways. Molecular Pathways, 14(5), 1291–1296.

Oun, R., Moussa, Y. E., & Wheat, N. J. (2018). The Side Effects Of Platinum-Based Chemotherapy Drugs: A Review For Chemists. Dalton Trans, 47(19), 6645–6653.

Shen, D., Pouliot, L. M., Hall, M. D., &Gottesman, M. M. (2012). Cisplatin Resistance : A Cellular Self-Defense Mechanism Resulting From Multiple Epigenetic And Genetic Changes. Pharmacological Reviews, 64(3), 706-721.

Downloads

Published

27-05-2020

Issue

Vol. 11 No. 1 (2020): Jurnal Kesehatan

Section

Articles

License

Authors who publish in this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.